Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvana Novelli

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
British Journal of Haematology|November 30, 2019
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)Leyre Bento, Antonio Díaz-López, Gilberto Barranco, et al.
Transplantation and Cellular Therapy|April 15, 2021
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO CentersSilvana Novelli, Leyre Bento, Irene Garcia, et al.
American Journal of Hematology|August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European centerPierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
European Journal of Haematology|December 6, 2019
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab eraAntonio Gutierrez, Leyre Bento, Antonio Diaz-Lopez, et al.
Cancers|June 10, 2022
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO ExperienceAntonio Gutierrez, Leyre Bento, Silvana Novelli, et al.
Bone Marrow Transplantation|March 26, 2021
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO studyLeyre Bento, Antonio Gutiérrez, Silvana Novelli, et al.
British Journal of Haematology|January 21, 2017
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β<sub>2</sub> -microglobulin yields a more accurate GELTAMO-IPICarlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, et al.
Haematologica|March 24, 2022
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL studyAlejandro Martín García-Sancho, Monica Bellei, Miriam López-Parra, et al.
British Journal of Haematology|August 8, 2017
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO groupSara Alonso-Álvarez, Laura Magnano, Miguel Alcoceba, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
British Journal of Haematology|November 30, 2019
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)Leyre Bento, Antonio Díaz-López, Gilberto Barranco, et al.
Transplantation and Cellular Therapy|April 15, 2021
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO CentersSilvana Novelli, Leyre Bento, Irene Garcia, et al.
American Journal of Hematology|August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European centerPierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
European Journal of Haematology|December 6, 2019
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab eraAntonio Gutierrez, Leyre Bento, Antonio Diaz-Lopez, et al.
Cancers|June 10, 2022
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO ExperienceAntonio Gutierrez, Leyre Bento, Silvana Novelli, et al.
Bone Marrow Transplantation|March 26, 2021
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO studyLeyre Bento, Antonio Gutiérrez, Silvana Novelli, et al.
British Journal of Haematology|January 21, 2017
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β<sub>2</sub> -microglobulin yields a more accurate GELTAMO-IPICarlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, et al.
Haematologica|March 24, 2022
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL studyAlejandro Martín García-Sancho, Monica Bellei, Miriam López-Parra, et al.
British Journal of Haematology|August 8, 2017
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO groupSara Alonso-Álvarez, Laura Magnano, Miguel Alcoceba, et al.
Pageof 7